Table 4.
Baseline clinical characteristics of non-familial prostate cancer patients.
| Clinical variables | Clinical cases (n = 2283) | Screening trial cases (n = 455) |
|---|---|---|
| Age at diagnosis | ||
| Early onset (≤ 55 y) | 103 (4.50) | 3 (0.70) |
| Late onset (> 55 y) | 2180 (95.5) | 452 (99.3) |
| Diagnostic PSA level, ng/mL | ||
| Low, ≤ 20 | 1684 (73.8) | 415 (91.2) |
| High, > 20 | 455 (19.9) | 29 (6.40) |
| Missing data | 144 (6.30) | 11 (2.40) |
| Gleason score | ||
| Low, ≤ 6 | 1033 (45.3) | 287 (63.1) |
| High, ≥ 8 | 329 (14.4) | 39 (8.60) |
| Gleason 7 | 564 (24.7) | 121 (26.6) |
| Missing data | 357 (15.6) | 8 (1.80) |
| T stage | ||
| T0/Tx | 0 (0.00) | 13 (2.90) |
| T1 | 746 (32.8) | 359 (78.9) |
| T2 | 922 (40.3) | 50 (11.0) |
| T3 | 418 (18.3) | 25 (5.50) |
| T4 | 96 (4.20) | 1 (0.20) |
| Missing data | 101 (4.40) | 7 (1.50) |
| N stage | ||
| N0/Nx | 2169 (95.0) | 447 (98.2) |
| N1 | 13 (0.60) | 1 (0.20) |
| Missing data | 101 (4.40) | 7 (1.50) |
| M stage | ||
| M0/Mx | 1999 (87.6) | 440 (96.7) |
| M1 | 183 (8.00) | 8 (1.80) |
| Missing data | 101 (4.40) | 7 (1.50) |
| PSA Progression | ||
| Progressed | 804 (35.4) | 156 (34.3) |
| Missing data | 1479 (64.8) | 299 (65.7) |
| Death | ||
| Deceased of PC | 296 (13.0) | 8 (1.76) |
| Deceased of else | 864 (37.9) | 63 (13.9) |
| Alive | 1123 (49.2) | 384 (84.4) |